Startseite>>Myelin Basic Protein Peptide Antagonist (trifluoroacetate salt)

Myelin Basic Protein Peptide Antagonist (trifluoroacetate salt)

Katalog-Nr.GC90558

Ein MBP-Antagonist

Products are for research use only. Not for human use. We do not sell to patients.

Myelin Basic Protein Peptide Antagonist (trifluoroacetate salt) Chemische Struktur

Größe Preis Lagerbestand Menge
1 mg
40,00 $
Auf Lager
5 mg
180,00 $
Auf Lager
10 mg
317,00 $
Auf Lager
25 mg
695,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Myelin basic protein (MBP) peptide antagonist is a synthetic peptide antagonist against the multiple sclerosis (MS) autoantigen MBP.1 MBP peptide antagonist binds to the immunomodulatory region of MBP, corresponding to residues 85-99 and inhibits MBP binding to human HLA-DR2 in a concentration-dependent manner. It inhibits the production of IL-2 in T cell bridoma cells expressing an MBP (85-99)-specific T cell receptor derived from a patient with multiple sclerosis. MBP peptide antagonist also delays MBP (85-99)-induced experimental autoimmune encephalomyelitis (EAE) onset and reduces EAE symptom severity in double-transgenic humanized mice expressing human HLA-DR2 and MBP (85-99)-specific T cell receptor antigen in a model of MS when administered at a dose of 100 µg/animal.

Bewertungen

Review for Myelin Basic Protein Peptide Antagonist (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Myelin Basic Protein Peptide Antagonist (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.